Seasoned biopharma leader and former cardiothoracic surgeon steps in as lead candidate S-969 moves closer to IND filing
RENO, NV, UNITED STATES, July 17, 2026 /EINPresswire.com/ — Sarcomatrix Therapeutics, a biopharmaceutical firm focused on creating novel treatments for Duchenne muscular dystrophy (DMD), has announced the appointment of Jeff Myers, M.D., Ph.D., as Chief Medical Officer. Dr. Myers arrives at the company as Sarcomatrix pushes its lead small-molecule candidate, S-969, toward Investigational New Drug (IND) submission and initial human trials.
Dr. Myers possesses over 15 years of executive-level experience overseeing clinical development, regulatory strategy, medical affairs, and worldwide clinical operations within biotechnology companies that create innovative therapies. Before coming to Sarcomatrix, he occupied high-level executive roles, including Chief Medical Officer at Beyond Air, Revolo Biotherapeutics, and Portola Pharmaceuticals. Earlier in his professional journey, he worked as a congenital cardiothoracic surgeon and led pediatric cardiac surgery divisions at both Massachusetts General Hospital and Tulane University.
"Jeff's track record of guiding first-in-class treatments from development through clinical execution makes him a superb fit for our executive team," stated David Craig, Co-Founder and Chief Executive Officer of Sarcomatrix Therapeutics. "As we get ready to begin clinical work, his knowledge of clinical development, regulatory strategy, and translational medicine will prove tremendously valuable as we move S-969 toward individuals affected by Duchenne muscular dystrophy."
In his role as Chief Medical Officer, Dr. Myers will offer strategic direction for Sarcomatrix's clinical development program. This includes finalizing the Phase I clinical strategy, aiding regulatory discussions, directing CRO selection, and helping advance the company's primary therapeutic candidate toward clinical assessment.
"I am thrilled to become part of Sarcomatrix at this pivotal moment in the company's progress," remarked Dr. Myers. "The scientific basis underlying S-969 and the chance to possibly enhance results for individuals living with Duchenne muscular dystrophy are exceptionally compelling. I anticipate collaborating with David and the whole team as we shift from preclinical development into clinical trials."
S-969 is an investigational oral small-molecule therapy being created to target the fundamental muscle deterioration linked to Duchenne muscular dystrophy, a rare, progressive neuromuscular condition that affects roughly one in every 3,500 to 5,000 male births globally.
About Sarcomatrix Therapeutics
Sarcomatrix Therapeutics is a biopharmaceutical enterprise developing novel oral treatments for Duchenne muscular dystrophy and associated neuromuscular conditions. The company's primary investigational candidate, S-969, is intended to enhance muscle performance and decelerate disease advancement through a distinct mechanism of action. Sarcomatrix is progressing S-969 toward clinical development with the aim of providing accessible therapies that enhance the lives of patients suffering from devastating neuromuscular diseases.
Media Contact
Madelyn De Los Santos
Putnam Insights LLC
madelyn@putnaminsights.com
